GSK (NYSE:GSK) announced Thursday that the U.S. FDA has further broadened the label for its asthma therapy, approving the ...

The COPD approval marks the fifth Nucala has received from the FDA, following green lights in severe asthma, chronic rhinosinusitis with nasal polyps, eosinophilic granulomatosis with polyangiitis and ...

The U.S. Food and Drug Administration has approved British drugmaker GSK's asthma drug to treat some patients with a chronic ...